Treeway announces Orphan Drug Designation for TW001
1 December 2014 | By Treeway
Treeway B.V. is pleased to announce that the European Medicines Agency has granted orphan drug designation for TW001 for the treatment of ALS...
List view / Grid view
News
Futura Medical plc update on pain relief clinical programme
1 December 2014 | By Futura Medical
Futura Medical plc, the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it will shortly be making a submission to UK regulators for approval to begin a clinical study to assess the efficacy and safety of its three topical pain relief products, which have already…
First monthly flu vaccination figures released
28 November 2014 | By Public Health England
Almost two months since the launch of the seasonal flu vaccine campaign, the first monthly uptake figures show an encouraging start, but Public Health England (PHE) is urging all at risk people not to ‘put off’ getting the vaccination until flu is circulating more widely...
ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV
27 November 2014 | By ViiV Healthcare
Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...
Freshers told ‘it’s not too late’ for MenC vaccine
27 November 2014 | By Public Health England
Recent reports of meningitis and septicaemia cases in students...
Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
27 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU...
Bristol-Myers Squibb receives complete Response Letter from U.S. Food and Drug Administration for daclatasvir, an investigational treatment for Hepatitis C
27 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C...
Action required to tackle EU alcohol consumption
27 November 2014 | By European Alcohol Policy Alliance
Today over 300 representatives from Health Ministries, the European Institutions, public health experts and concerned stakeholders have gathered in Brussels to call on the European Commission President Jean-Claude Juncker and his team to take actions to prevent and reduce the burden of alcohol on European societies...
Apitope receives Orphan designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A
26 November 2014 | By Apitope
Treatment for haemophilia A patients developing Factor VIII inhibitors...
Europe’s biopharmaceutical industry faces highest business risks among six key industry sectors, according to first-of-its-kind comparative study
26 November 2014 | By Janssen
Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, study concludes...
QbD in Pharma Development World Congress 2015
26 November 2014 | By SELECTBIO
SELECTBIO is organizing the 3rd Annual International QbD conference “QbD in Pharma Development World Congress 2015” with the theme "Emerging Challenges, Federal Issues & Possible Solutions" scheduled to be held on April 16-18, 2015 in Hotel Shivalik View, Chandigarh, India...
Cardio3 Biosciences announces the nomination of three co-principal investigators for its chart-2 Phase iii clinical trial of C-Cure® for the treatment of heart failure
26 November 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the appointment of its three Co-Principal Investigators for the CHART-2 study (Congestive Heart Failure cArdiopoietic Regenerative Therapy), authorized in the United States by the FDA in January, and anticipated to start by the end of 2014...
Transmission Raman method gains regulatory approval for content uniformity batch release test
25 November 2014 | By Cobalt Light Systems
Cobalt Light Systems is pleased to announce that a major pharmaceutical company has gained regulatory approval to release products using Cobalt’s TRS100 instrument instead of by HPLC...
European Commission approves Rezolsta, a new once-daily, fixed-dose HIV therapy combining darunavir and cobicistat
25 November 2014 | By Janssen
Janssen-Cilag International NV announced that the European Commission (EC) has approved the use of REZOLSTA® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older...
Promethera Biosciences raises €25.33 million ($31.4 million) in Series C financial round
25 November 2014 | By Promethera Biosciences
Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital...
